Last updated on July 2019

Open-label Clinical Trial of Lacosamide in ALS


Brief description of study

Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS).

Detailed Study Description

Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS). This clinical trial is open-label, single group and before and after comparison study. Dosage of lacosamide is increased from 100mg to 400mg for 4 weeks. Safety of lacosamide administration in ALS is primary endpoint. Nerve excitability, fasciculation and muscle cramp are investigated before and after administration for secondary endpoints.

Clinical Study Identifier: NCT03186040

Find a site near you

Start Over